Fintel reports that on April 8, 2025, HC Wainwright & Co. initiated coverage of VolitionRx (NYSEAM:VNRX) with a Buy ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.31, a high ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

H.C. Wainwright analyst Yi Chen initiated coverage of VolitionRx (VNRX) with a Buy rating and $2.50 price target VolitionRx is a diagnostics ...

H.C. Wainwright raised the firm’s price target on Pacira (PCRX) to $65 from $48 and keeps a Buy rating on the shares. The firm believes the ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

Shares of Pacira BioSciences Inc (PCRX) traded 19% higher on Tuesday morning, following upward price target revisions by ...